Assignee
NURIX THERAPEUTICS INC
US·21 granted patents·19 pending applications·68 citations·filing 2019–2025
Top patents by PatentIndex Score
40 records- 0197US11530229B2Cyano cyclobutyl compounds for CBL-B inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Dec 20, 2022·12 cites·71 claims
- 0297US11464802B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Oct 11, 2022·14 cites·53 claims
- 0397US11401267B2Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Aug 2, 2022·11 cites·32 claims
- 0494US11951133B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Apr 9, 2024·2 cites·36 claims
- 0594US11866442B2Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2022·Granted Jan 9, 2024·5 cites·37 claims
- 0693US11479556B1Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2019·Granted Oct 25, 2022·9 cites·106 claims
- 0792US12485144B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2024·Granted Dec 2, 2025·1 cites·40 claims
- 0892US12049471B2Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Jul 30, 2024·1 cites·16 claims
- 0991US11739101B2Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2021·Granted Aug 29, 2023·3 cites·40 claims
- 1090US12234230B2Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Feb 25, 2025·1 cites·5 claims
- 1188US11976071B2Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinasesNURIX THERAPEUTICS INC·Filed 2022·Granted May 7, 2024·2 cites·14 claims
- 1288US11820781B2Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2020·Granted Nov 21, 2023·5 cites·34 claims
- 1388US2026035378A1Bifunctional compounds for degrading btk via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1483US12121540B2CBL inhibitors and compositions for use in adoptive cell therapyNURIX THERAPEUTICS INC·Filed 2020·Granted Oct 22, 2024·1 cites·48 claims
- 1583US12016860B2Combination therapies with Cbl-b inhibitor compoundsNURIX THERAPEUTICS INC·Filed 2022·Granted Jun 25, 2024·1 cites·4 claims
- 1681US12583862B2Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2023·Granted Mar 24, 2026·0 cites·19 claims
- 1781US2025136590A1Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1880US2024409555A1Cyano cyclobutyl compounds for cbl-b inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1976US12570662B2Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinasesNURIX THERAPEUTICS INC·Filed 2024·Granted Mar 10, 2026·0 cites·20 claims
- 2073US2024400587A1Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2171US12377106B2Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTKNURIX THERAPEUTICS INC·Filed 2022·Granted Aug 5, 2025·0 cites·34 claims
- 2269US2025161303A1Combination therapies with cbl-b inhibitor compoundsNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2368US12091426B2Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Sep 17, 2024·0 cites·29 claims
- 2467US2024025923A1Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2565US2023414598A1Combination therapies with cbl-b inhibitor compounds and antiemetic agentsNURIX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2663US2025136579A1Salts and free bases of bifunctional compound and polymorph forms thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2760US2025017922A1Bifunctional compounds for degrading btk with enhanced imid activityNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2858US2023158151A1Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their useNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2958US2024336595A1Bifunctional compounds for degrading btk with diminished imid activityNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3057US2024279202A1Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their useNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3156US2023355599A1Biomarkers for cbl, and compositions and methods for their useNURIX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3256US2025002489A1Bifunctional compounds for degrading itk via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3355US12594263B2CBL inhibitors and compositions for expansion of immune cellsNURIX THERAPEUTICS INC·Filed 2020·Granted Apr 7, 2026·0 cites·31 claims
- 3454US12528814B2Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereofNURIX THERAPEUTICS INC·Filed 2021·Granted Jan 20, 2026·0 cites·57 claims
- 3553US2025009731A1Toll-like receptor therapy combinations with cbl-b inhibitor compoundsNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3651US2022387395A1Urea, amide, and substituted heteroaryl compounds for cbl-b inhibitionNURIX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3750US2022324835A1Inhibitors of cbl-b and methods of use thereofNURIX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3850US2025051344A1Bifunctional selective degraders of smarca2 and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3944US2023024442A1Bifunctional compounds for grading btk via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4043US12582722B2Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2020·Granted Mar 24, 2026·0 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when NURIX THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →